Drug and Therapeutics Bulletin 2006;44:49-53; doi:10.1136/dtb.2006.44749
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Managing Bell's palsy

Each year in the UK, around 1 in 5,000 people develop Bell's palsy – a unilateral lower motor neurone facial weakness of rapid onset that can be physically and psychologically disabling.¹ While around 71% of patients recover normal function of the facial muscles without treatment, 13% are left with slight weakness and 16% with moderate to severe weakness resulting in major facial dysfunction.^2,3 People who recover usually do so quickly, with 85% of them reporting some improvement in the first 3 weeks.² There is longstanding controversy about what, if any, treatment should be initiated for Bell's palsy. Here we discuss the management of patients with this condition.

This article has been cited by other articles:

				Update on managing bell's palsy DTB, July 1, 2008; 46(7): 53 - 54. [Abstract] [Full Text] [PDF]